Cart
sales@molnova.com
Talniflumate
CAS No. 66898-62-2
Talniflumate( Talniflumate )
Catalog No. M18975 CAS No. 66898-62-2
Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 42 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 141 | In Stock |
|
| 50MG | 231 | In Stock |
|
| 100MG | 384 | In Stock |
|
| 200MG | 548 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTalniflumate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTalniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture.
-
DescriptionTalniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome.(In Vivo):Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction.
-
In Vitro——
-
In VivoTalniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction. Animal Model:CF mice with distal intestinal obstructive syndrome (DIOS)Dosage:0.4 mg/g Administration:Oral chow; 21 days Result:Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
-
SynonymsTalniflumate
-
PathwayOthers
-
TargetOther Targets
-
RecptorhCLCA1/mCLCA3|COX|Cl-/HCO3- exchanger|GCNT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number66898-62-2
-
Formula Weight414.33
-
Molecular FormulaC21H13F3N2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (150.85 mM)
-
SMILESFC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1
-
Chemical Name2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Knight D. Talniflumate (Genaera)[J]. Current Opinion in Investigational Drugs, 2004, 5(5):557-62.
molnova catalog
related products
-
Dehydrocostuslactone
Dehydrocostuslactone is a natural product extracted from Aucklandia.
-
Indecainide
Indecainide (Ricainid) is a novel antiarrhythmic compound that is carcinogenic and can be used to study chronic stable ventricular arrhythmias secondary to coronary artery disease or cardiomyopathy.
-
26Rfa, Hypothalamic ...
This human neuropeptide of the RFamide peptide family with orexigenic activity may be also involved in the control of feeding behavior. The 26RFa gene is exclusively expressed in the ventromedial hypothalamic nucleus and in the lateral hypothalamic area. The primary structures of human, rat, and frog 26RFa exhibit ≈80% identity. Other data suggest also the potential role of the 26RFa peptide in the control of the gonadotropic axis.
